1 matches for your search in the start-up spotlight
rss
matching the following criteria
Sort by:
Eisbach Bio GmbH
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s ...
